Pivotal Treatment in Breast Cancer Education Center

Approximately 20% of patients diagnosed with breast cancer have a type of cancer that is positive for the human epidermal growth factor receptor 2 (HER2) protein. HER2 positive breast cancers are unique due to the significant efficacy of treatments that target the HER2 protein. Furthermore, treatments for HER2 positive breast cancer are effective for both patients with early stage and metastatic breast cancer. Recent advances in the treatment of HER positive breast cancer continue to dramatically improve outcomes for these patients.

This Education Center is intended to update clinicians on the latest developments in HER positive breast cancer in order to help them more effectively treat patients.

Novel HER2 Vaccine Shows Efficacy, Safety in Early Clinical Trial

Novel HER2 Vaccine Shows Efficacy, Safety in Early Clinical Trial

Imugene recently announced that its investigational Human Epidermal Growth Factor Receptor 2 (HER2) vaccine demonstrated positive safety results and promising efficacy data in an early clinical trial...
FDA Approves Trastuzumab Biosimilar for Breast Cancer

FDA Approves Trastuzumab Biosimilar for Breast Cancer

The FDA approved trastuzumab-pkrb, a HER2/neu receptor antagonist biosimilar to trastuzumab, for the treatment of certain patients with breast cancer, according to the manufacturers...
Incontinence Drug May Ease Hot Flashes in Women with Breast Cancer

Incontinence Drug May Ease Hot Flashes in Women with Breast Cancer

A low dose of oxybutynin, an anticholinergic used to treat incontinence associated with overactive bladder, reduces hot flashes and improves quality of life in breast-cancer survivors, according to a new study...
Exercise During Adjuvant Breast-Cancer Treatment Good for the Heart

Exercise During Adjuvant Breast-Cancer Treatment Good for the Heart

A supervised exercise program during adjuvant therapy for breast cancer improved cardiopulmonary function in women enrolled in the EBBA-II trial...

Loading...

© 2024 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use | Editorial Policy | Advertising Policy